Wide Ranks

BLUE

bluebird bio, Inc.

0.3778

Top Statistics
Market Cap 73 M Forward PE -0.5083 Revenue Growth 133.70 %
Current Ratio 0.68 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.06 Enterprise / Revenue 5.86 Price To Sales Trailing12 Months 1.34
Profitability
Profit Margins 0.00 % Operating Margins -548.99 %
Balance Sheet
Total Cash 144 M Total Cash Per Share 0.7430 Total Debt 395 M
Total Debt To Equity 746.76 Current Ratio 0.68 Book Value Per Share 1.01
All Measures
Short Ratio 953.00 % Message Board Id finmb_28921 Shares Short Prior Month 48 M
Return On Equity -1.87 City Somerville Uuid 1b3e1ee9-bff8-3431-9ea6-b181365ba65f
Previous Close 0.3700 First Trade Date Epoch Utc 1 B Book Value 1.01
Beta 0.8030 Total Debt 395 M Volume 4 M
Price To Book 0.3744 Last Split Date 1 B Fifty Two Week Low 0.2900
Total Cash Per Share 0.7430 Total Revenue 54 M Shares Short Previous Month Date 1 B
Target Median Price 2.00 Audit Risk 9 Max Age 86400
Recommendation Mean 2.90 Sand P52 Week Change 0.3133 Operating Margins -548.99 %
Target Mean Price 2.36 Net Income To Common -319251008 Short Percent Of Float 0.2666
Implied Shares Outstanding 194 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 5 M Average Volume10days 5 M Total Cash 144 M
Next Fiscal Year End 1 B Revenue Per Share 0.3570 Held Percent Insiders 0.0063
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 5 Regular Market Previous Close 0.3700 Target Low Price 0.5000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.4508 Open 0.3690
Free Cashflow -163919632 State MA Dividend Yield 0.00 %
Return On Assets -0.3624 Time Zone Short Name EST Board Risk 2
Trailing Eps -1.80 Day Low 0.3601 Address1 455 Grand Union Boulevard
Shares Outstanding 194 M Compensation Risk 3 Price Hint 4
Target High Price 6.00 Website https://www.bluebirdbio.com 52 Week Change -0.9005
Average Volume 6 M Forward Eps -0.6500 Recommendation Key hold
Compensation As Of Epoch Date 1 B Quick Ratio 53.20 % Last Split Factor 1544:1000
Regular Market Day High 0.3870 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 746.76 Fifty Two Week High 5.53 Day High 0.3870
Shares Short 47 M Regular Market Open 0.3690 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 5.86 Revenue Growth 133.70 %
Shares Percent Shares Out 0.2460 Operating Cashflow -245115008 Currency USD
Time Zone Full Name America/New_York Market Cap 73 M Is_nasdaq_100 False
Zip 02145 Quote Type EQUITY Industry Biotechnology
Long Name bluebird bio, Inc. Overall Risk 4 Regular Market Day Low 0.3601
Held Percent Institutions 0.4369 Current Price 0.3778 Enterprise To Ebitda -1.06
Financial Currency USD Current Ratio 0.68 Gross Margins -38.67 %
Industry Disp Biotechnology Number Of Analyst Opinions 7 Country United States
Float Shares 193 M Two Hundred Day Average 0.8847 Governance Epoch Date 1 B
Enterprise Value 321 M Price To Sales Trailing12 Months 1.34 Forward PE -0.5083
Regular Market Volume 4 M Ebitda -302105984 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States.

The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.

The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010.

bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.